The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

The BIOFIRE® Respiratory 2.1 (RP2.1) Panel use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results …

The BioFire RP2.1 is a real-time, nested multiplexed polymerase chain reaction test designed to simultaneously identify nucleic acids from 22 different viruses and bacteria associated with ...

The BioFire Respiratory 2.1 Panel (RP2.1) is a multiplex polymerase chain reaction (PCR) test that identifies nucleic acids from 23 difer-ent bacteria and viruses that commonly cause upper and...

The FDA-cleared and CLIA-waived BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel is a user-friendly diagnostic test that identifies up to 15 targets associated with respiratory and sore …

The BioFire RP2.1 Panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. Fast and comprehensive, the BioFire RP2.1 …

The BIOFIRE Respiratory 2.1 and 2.1plus Panels are frontline tests to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

This procedure provides instructions for testing nasopharyngeal swabs (NPS) collected in transport media or saline, using the BioFire® Respiratory Panel 2.1 (RP2.1) Kit (423742).

The BIOFIRE RP2.1 is a real-time, nested multiplexed polymerase chain reaction test designed to simultaneously identify nucleic acids from 22 different viruses and bacteria associated with …

BioFire’s syndromic approach combines a broad grouping of probable pathogens into a single, rapid test. With the BioFire RP2.1plus Panel, all it takes is one test and just 45 minutes to identify 23 …